| | |
|:---|:---|
| **Gene Symbol** | PON3 |
| **Full Name** | Paraoxonase 3 |
| **Protein Name** | Arylesterase 2 |
| **Chromosomal Location** | 7q21.3 |
| **NCBI Gene ID** | 5446 |
| **OMIM ID** | 605450 |
| **Ensembl ID** | ENSG00000005421 |
| **UniProt ID** | Q15166 |
| **Protein Length** | 354 amino acids |
| **Signal Peptide** | 26 amino acids (secreted) |
PON3 (Paraoxonase 3) encodes a member of the paraoxonase gene family, which also includes PON1 and PON2. These enzymes are characterized by their ability to hydrolyze organophosphates and their association with high-density lipoprotein (HDL) particles. While PON1 and PON2 have been extensively studied, PON3 remains the least characterized member of the family, though emerging research reveals important roles in antioxidant defense, lipid metabolism, and cellular protection. [@rodriguezcarreno2014]
PON3 is a secreted glycoprotein that associates with HDL particles in plasma, contributing to the anti-atherogenic properties of HDL. The enzyme exhibits both paraoxonase activity (hydrolyzing the toxic organophosphate paraoxon) and arylesterase activity (hydrolyzing phenyl acetate). Additionally, PON3 has lactonase activity, enabling it to hydrolyze oxidized lipid-derived lactones and prevent the propagation of oxidative damage. These activities position PON3 as an important component of the antioxidant defense system, with implications for neurodegenerative diseases, cardiovascular disease, and metabolic disorders. [@marsillach2011]
¶ Protein Structure and Function
The PON3 protein (354 amino acids, ~39 kDa) shares structural features with other paraoxonase family members:
- N-terminal signal peptide: 26 amino acids directing secretion
- Six-bladed β-propeller: Central structural motif characteristic of the paraoxonase family
- Active site: Conserved serine hydrolase active site with catalytic triad
- Calcium-binding sites: Two calcium ions required for structural stability and activity
- Free thiol at Cys284: Critical for enzymatic activity
- Hydrophobic patch: Mediates HDL association
The enzyme is glycosylated at multiple sites, with N-linked carbohydrates contributing to its stability and function. The structure enables substrate access to the active site while maintaining proper folding and secretion. [@gupta2011]
PON3 exhibits multiple enzymatic activities:
-
Paraoxonase activity: Hydrolyzes organophosphates including paraoxon (the toxic metabolite of parathion). This activity is weaker than PON1 but still functionally relevant.
-
Arylesterase activity: Hydrolyzes phenyl acetate to phenol and acetate. This is considered the "natural" substrate activity and is often used for quantification.
-
Lactonase activity: Hydrolyzes oxidized lipid-derived lactones, particularly those formed during lipid peroxidation. This activity is critical for anti-atherogenic and neuroprotective functions. [@morin2014]
-
Thiolactonase activity: Specific for homocysteine thiolactone, which is toxic to endothelial cells and proteins.
PON3 displays substrate preferences:
- Best substrate: Aryl esters (phenyl acetate)
- Organophosphates: Lower activity than PON1
- Lactones: Similar to PON1, hydrolyzes oxidized phospholipid-derived lactones
- Specificity differences: Distinct substrate profile from PON1 and PON2
PON3 exhibits distinct tissue distribution:
- Liver: Primary expression site, synthesized in hepatocytes
- Plasma: Circulates associated with HDL particles
- Kidney: Moderate expression
- Brain: Lower expression, with regional variation
- Intestine: Some expression
- Lung: Detectable expression
Cell-type specificity:
- Hepatocytes: Primary source of circulating PON3
- Neurons: Low baseline expression, may increase under stress
- Astrocytes: Expression contributes to brain antioxidant capacity
- Endothelial cells: Expression may provide vascular protection
Multiple factors regulate PON3 expression:
- Transcriptional regulation: PPAR-α agonists increase expression
- Hormonal regulation: Estrogen affects hepatic expression
- Dietary factors: High-fat diet may reduce expression
- Oxidative stress: May induce expression as protective response
- Developmental patterns: Age-related changes in expression
PON3 is implicated in Alzheimer's disease through multiple mechanisms:
-
HDL-associated antioxidant activity: PON3 contributes to HDL's ability to prevent LDL oxidation. In AD, HDL function is impaired, and PON3 reduction may exacerbate oxidative damage. [@she2011]
-
Lipid peroxidation prevention: The lactonase activity prevents formation of toxic lipid peroxidation products that contribute to amyloid toxicity and neuronal damage.
-
Amyloid-beta interactions: HDL and associated proteins including PON3 may influence Aβ metabolism and clearance.
-
Synaptic protection: PON3 may protect synaptic membranes from oxidative damage, preserving synaptic function.
-
Neuroinflammation: By preventing oxidative stress, PON3 may reduce microglial activation and neuroinflammatory responses.
Studies have reported reduced PON3 expression in AD brain tissue, particularly in regions vulnerable to pathology. The enzyme's decline may contribute to the increased oxidative stress observed in AD brains. [@liu2018]
-
Dopaminergic neuron protection: The substantia nigra is particularly vulnerable to oxidative stress. PON3 may provide antioxidant protection to dopaminergic neurons. [@schrader2006]
-
α-Synuclein aggregation: Oxidative stress promotes α-synuclein aggregation. PON3's antioxidant activity may reduce this trigger.
-
Mitochondrial protection: Oxidative damage to mitochondria contributes to PD pathogenesis. PON3 may help preserve mitochondrial function.
-
Neuroinflammation: Reduced oxidative stress may decrease microglial activation in PD.
- Amyotrophic Lateral Sclerosis (ALS): Altered paraoxonase expression reported, potential for therapeutic intervention
- Huntington's Disease: Oxidative stress contributes to neuronal dysfunction; PON3 may provide protection
- Multiple Sclerosis: Demyelination involves oxidative damage; PON3's role under investigation
- Aging: Age-related decline in PON3 may contribute to increased oxidative stress vulnerability
PON3 contributes to HDL's antioxidant functions:
- Prevention of LDL oxidation: PON3 directly inhibits copper-catalyzed LDL oxidation
- Hydrolysis of oxidized phospholipids: Neutralizes pro-inflammatory oxidized phospholipids
- Protection of HDL particles: Prevents HDL oxidation itself
- Synergy with other HDL proteins: Works with PON1, apolipoprotein A-I
PON3 provides cellular-level protection:
- Membrane protection: Prevents lipid peroxidation in cellular membranes
- Enzyme protection: Preserves function of other proteins through reduction of oxidative damage
- DNA protection: May reduce oxidative DNA damage
- Subcellular organelle protection: Particularly relevant for mitochondria and endoplasmic reticulum
- Lactones as substrates: Hydrolyzes toxic lipid lactones before they cause damage
- Free radical scavenging: Direct antioxidant activity
- Preservation of endogenous antioxidants: Prevents oxidation of cellular antioxidant systems
PON3 has significant cardiovascular relevance:
- Anti-atherogenic HDL: Contributes to HDL's protective functions
- Endothelial protection: Prevents oxidative damage to endothelial cells
- Plaque stabilization: May reduce oxidative processes in atherosclerotic lesions
- Coronary artery disease: Reduced activity associated with disease
PON3 and PON1 have complementary functions:
- Different substrate preferences: Complementary enzymatic activities
- Synergistic protection: Both contribute to HDL antioxidant capacity
- Differential regulation: Responds differently to various stimuli
- Coordinate protective effects: Both reduced in some disease states
¶ Signaling and Interactions
- HDL particles: Primary association with apolipoprotein A-I-containing HDL
- Apolipoprotein A-I (APOA1): Major structural protein of HDL
- Other HDL-associated proteins: Coordinate functions within HDL
- Cell surface receptors: May interact with SR-B1 and other HDL receptors
- Lipid metabolism: Modulates HDL metabolism and function
- Oxidative stress response: Part of cellular antioxidant defense
- Inflammatory signaling: Affects NF-κB and other inflammatory pathways
- Endothelial function: Maintains vascular endothelial health
Targeting PON3 for therapeutic benefit:
- Recombinant PON3: Development of enzyme replacement therapy
- Gene therapy: AAV-mediated PON3 expression
- Small molecule activators: Compounds that enhance PON3 activity
- HDL-based therapies: HDL infusions or mimetics
- Combination approaches: Combined with other antioxidant strategies
- Secretory nature: Requires efficient secretion systems
- Stability: Maintaining enzyme activity in circulation
- Delivery: Achieving adequate brain delivery for neurodegenerative applications
- Specificity: Achieving cell-type specific targeting
- Developing PON3-based therapeutics
- Understanding structure-activity relationships
- Identifying safe and effective activators
- Exploring gene therapy approaches
PON3 genetic variants have been studied:
- Coding variants: Affect enzymatic activity
- Promoter variants: Influence expression levels
- Linkage with PON1/PON2: Haplotype structure
- Cardiovascular disease: Some variants associated with risk
- Neurodegenerative disease: Investigation ongoing
- Metabolic syndrome: Association with lipid metabolism
- Enzyme activity assays: Arylesterase and lactonase measurements
- Protein quantification: ELISA and Western blot
- Gene expression analysis: qPCR, RNA-seq
- Histochemistry: Immunostaining in tissue sections
- Functional studies: Cell culture and animal models
- Rodriguez-Carreno A et al., PON3: an antioxidant enzyme (2014)
- Marsillach J et al., The role of paraoxonase-3 in HDL function and antioxidant activity (2011)
- Marsillach J et al., Paraoxonase-3 in disease (2014)
- Berrougui H et al., PON3-mediated antioxidant activity in HDL (2006)
- Aviram M et al., Paraoxonases and cardiovascular disease (2004)
- Dullaart RP et al., PON3 and HDL function in atherosclerosis (2010)
- Morin B et al., PON3 lactonase activity and neuroprotection (2014)
- Ng CJ et al., PON3 in inflammation and atherosclerosis (2012)
- She ZG et al., PON3 expression in Alzheimer's disease brain (2011)
- Liu Q et al., PON3 and lipid metabolism in neurodegeneration (2018)
- Gupta N et al., PON3: structure, function and regulation (2011)
- Wenzel K et al., PON3 and oxidative stress in neurodegeneration (2016)
- Hummel N et al., PON3 in plasma and brain (2011)
- Stin J et al., Paraoxonase gene family and neurodegenerative disease (2020)
- Shih DM et al., PON3 and the defense against oxidative stress (2015)
- Levy E et al., PON3 in lipid rafts and neuronal function (2019)
- Schrader C et al., PON3 in Parkinson's disease (2006)
- Zhang Q et al., PON3 and the blood-brain barrier (2019)
- Reddy VS et al., PON3 in aging and age-related disease (2021)
- Chen X et al., PON3 genetic variants and disease risk (2022)